A Multi-Center, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of AMR101 on Cardiovascular Health and Mortality in Hypertriglyceridemic Patients with Cardiovascular Disease or at High Risk for Cardiovascular Disease: REDUCE-IT (Reduction of Cardiovascular Events with EPA – Intervention Trial)

Trial Profile

A Multi-Center, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of AMR101 on Cardiovascular Health and Mortality in Hypertriglyceridemic Patients with Cardiovascular Disease or at High Risk for Cardiovascular Disease: REDUCE-IT (Reduction of Cardiovascular Events with EPA – Intervention Trial)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 14 Aug 2017

At a glance

  • Drugs Ethyl eicosapentaenoic acid (Primary)
  • Indications Cardiovascular disorders; Hypertriglyceridaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms REDUCE-IT
  • Sponsors Amarin Corporation
  • Most Recent Events

    • 14 Aug 2017 According to an Amarin Corporation media release, results from the completed study are expected in Q2 or Q3 2018.
    • 14 Aug 2017 According to an Amarin Corporation media release, the independent data monitoring committee (DMC) has completed its review of the pre-specified interim efficacy and safety analysis for this study and has recommended that the trial continue as planned without modification.
    • 15 Mar 2017 Trial design published in the Clinical Cardiology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top